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Abstract 
β-arrestins are key regulators and signal 
transducers of G protein-coupled receptors 
(GPCRs). The interaction between receptors 
and β-arrestins is generally believed to require 
both receptor activity and phosphorylation by 
GPCR kinases. In this study, we investigated 
whether β-arrestins are able to bind second 
messenger kinase-phosphorylated, but inactive 
receptors as well. Since heterologous 
phosphorylation is a common phenomenon 
among GPCRs, this mode of β-arrestin 
activation may represent a novel mechanism of 
signal transduction and receptor cross-talk. 
Here we demonstrate that activation of 
protein kinase C (PKC) by phorbol myristate 
acetate, Gq/11-coupled GPCR or epidermal 
growth factor receptor stimulation promotes β-
arrestin2 recruitment to unliganded AT1 
angiotensin receptor (AT1R). We found that this 
interaction depends on the stability lock, a 
structure responsible for the sustained binding 
between GPCRs and β-arrestins, formed by 
phosphorylated serine-threonine clusters in the 
receptor’s C-terminus and two conserved 
phosphate-binding lysines in the β-arrestin2 N-
domain. Using improved FlAsH-based β-
arrestin2 conformational biosensors, we also 
show that the stability lock not only stabilizes the 
receptor-β-arrestin interaction, but also governs 
the structural rearrangements within β-
arrestins. Furthermore, we found that β-
arrestin2 binds to PKC-phosphorylated AT1R in 
a distinct active conformation, which triggers 
MAPK recruitment and receptor 
internalization. Our results provide new insights 
into the activation of β-arrestins and reveal their 
novel role in receptor cross-talk. 
 
 
The family of G protein-coupled receptors 
(GPCRs) consists of ~800 members in humans and 
about 30% of modern drugs target these molecules 
(1). GPCRs respond to a wide variety of 
endogenous ligands, including hormones, 
neurotransmitters, and lipids.  Despite their huge 
diversity, the signal transduction mechanisms of 
GPCRs share several common features: agonist 
binding is followed by the activation of a relatively 
small number of heterotrimeric G proteins, which 
initiate complex intracellular signaling cascades. 
Receptor responsiveness to further stimulation is 
attenuated by a multistep process, called 
desensitization (2). In case of homologous 
desensitization, active GPCRs are phosphorylated 
by GPCR kinases (GRKs) followed by the 
recruitment of β-arrestin proteins (β-arrestin1 and 
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β-arrestin2, also known as arrestin-2 and arrestin-3, 
respectively). β-arrestins uncouple the receptors 
from G proteins and initiate receptor internalization 
(3), thereby serving as the key regulators of 
GPCRs’ function. In contrast, heterologous 
desensitization is mediated by second-messenger 
activated kinases, such as protein kinase C (PKC), 
which can phosphorylate active and inactive 
receptors. Heterologous desensitization was 
originally thought to be independent of β-arrestins, 
however, some data have challenged this concept 
(4–6). In addition to their role in receptor 
desensitization and internalization, receptor-bound 
β-arrestins participate in signal transduction. In this 
function, β-arrestins serve as scaffolds for signal 
transducer proteins and initiate a broad range of 
signaling events. These include activation of 
mitogen-activated protein kinase (MAPK) 
signaling pathways, including ERK1/2, p38 and c-
Jun N-terminal kinase-3, as well as c-Src family 
kinases, AKT, phosphatidylinositol 3-kinase and 
phosphodiesterase 4 (7, 8). 
 Arrestins are elongated molecules, 
composed of two “cup-like” (N and C) domains. In 
inactive arrestins the C-terminus is bound to the N-
domain. Arrestins are activated by receptor 
docking, which takes place in two-steps (9, 10). 
First, in a process called “C-terminal swap”, 
arrestin releases its C-teminus, and its N-domain 
binds the phosphorylated receptor C-terminus. 
Then the “finger loop” of arrestin interacts with the 
cavity in the transmembrane helix bundle that 
opens in the activated receptor. The interaction 
between receptor C-terminus and β-arrestin 
determines the stability of the complex, based on 
which the receptors were categorized as belonging 
to class A or class B (11).  Class A-type binding is 
weak and transient, and can only be detected at the 
plasma membrane. In contrast, the tight and stable 
class B interaction results in co-internalization of 
receptor and β-arrestin into endosomes. The 
interaction stability has important functional 
consequences: class B-type binding is associated 
with stronger MAPK activation (12), and drives 
receptors to lysosomes instead of recycling 
endosomes after internalization (13). It is known 
that phosphorylated serine-threonine clusters in the 
receptor C-terminus participate in the stabilization 
of the arrestin-receptor complex (14), however, the 
structural basis of stable β-arrestin-receptor 
coupling is still poorly understood.  
In a recent study, it was shown that the 
state, in which β-arrestin interacts solely with the 
receptor C-terminus, is much more prevalent in the 
case of class B than class A receptors (15). A likely 
explanation for this phenomenon may be the 
difference in lifetime of C-terminal binding. 
Although active receptor state is thought to be a 
prerequisite for β-arrestin binding (16), the former 
finding suggests that β-arrestins may bind to 
inactive receptors as well, if a structural basis of 
stable interaction with phosphorylated receptor C-
terminus is present. Namely, the phosphorylation of 
receptor C-termini in proper positions might be 
sufficient for β-arrestins to engage the receptors via 
their N-domain. GRKs, the main GPCR kinases, 
preferentially phosphorylate the active receptors. In 
contrast, receptor phosphorylation by other kinases, 
such as PKC, occurs regardless of receptor 
activation. Thus, β-arrestin recruitment induced 
solely by receptor phosphorylation may serve as a 
novel physiological mechanism of β-arrestin 
activation. In some cases it has been suggested that 
PKC-dependent phosphorylation regulates the 
receptor function through β-arrestins (4–6, 17). It 
was reported that the PKC-induced internalization 
of the δ-opioid or the D2 dopamine receptors was 
suppressed by overexpression of dominant negative 
β-arrestin, and the β-arrestin-dependent 
desensitization of the calcium sensing receptor 
required phosphorylation by PKC. But to the best 
of our knowledge, receptor-β-arrestin interaction 
induced by PKC has been directly demonstrated 
only once with the α1B-adrenergic receptor (6). In 
the case of AT1 angiotensin receptor (AT1R), 
heterologous phosphorylation and desensitization 
was thought to be independent of β-arrestins (18). 
Here we show that activation of PKC by 
phorbol ester, α1A-adrenergic receptor, or epidermal 
growth factor receptor stimulation, leads to β-
arrestin2 (βarr2) recruitment to the AT1R. This 
recruitment is independent of AT1R activation, but 
relies on the stability lock, the interaction 
responsible for sustained binding between GPCRs 
and β-arrestin2. Using improved versions of 
recently described FlAsH-BRET sensors, we show 
that β-arrestin2 activated by PKC-phosphorylated 
receptor undergoes different conformational 
changes than in the case of full engagement. 
Selective disruption of the interaction-stabilizing 
elements showed that the stability lock not only 
sustains the receptor-β-arrestin interaction, but also 
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governs the structural rearrangements within β-
arrestin2. β-arrestin activated by PKC-
phosphorylated GPCR binds MEK1 and ERK2 and 
initiates receptor endocytosis, resulting in a 
different fate of internalized receptor.  
 
Results 
  
PKC activation leads to the recruitment of β-
arrestin2 to inactive AT1R 
It has been demonstrated previously that 
PKC phosphorylation sites in the AT1R C-terminus 
overlap with the GRK target sites (19, 20). 
Therefore, we tested whether C-terminal 
phosphorylation by PKC, in the absence of receptor 
stimulation, can induce β-arrestin2 binding to the 
receptor. To this end, we performed co-
precipitation experiments in HEK 293T cells co-
expressing YFP- and biotin acceptor peptide 
(BAP)-tagged AT1R, β-arrestin2-Cerulean, and 
biotin ligase (BirA). We stimulated the cells with 
either AT1R agonist angiotensin II (AngII) or 
specific PKC-activator phorbol myristate acetate 
(PMA) for 20 minutes, and co-precipitated β-
arrestin2-Cerulean with biotin-labeled receptors 
using NeutrAvidin beads. Strikingly, we found that 
both AngII and PMA induced β-arrestin2 binding 
to AT1R (Figure 1a). To determine the kinetics of 
heterologous β-arrestin2 binding in real time, we 
measured bioluminescence resonance energy 
transfer (BRET) between Rluc8-tagged AT1R and 
β-arrestin2-Venus (Figure 1b). Both PMA and 
AngII led to an increase of the BRET signal, 
reflecting the interaction between AT1R and β-
arrestin2 (Figure 1c). However, the PMA-induced 
β-arrestin2 binding to AT1R was delayed, 
suggesting that β-arrestin associates slower with 
inactive phosphorylated receptors than with active 
phosphorylated receptors. Physiologically, PKC is 
activated by stimulation of Gq/11-coupled GPCRs or 
growth factor receptors (21). To test whether β-
arrestin2 interacts with AT1R upon activation of a 
Gq/11-coupled GPCR, we co-expressed the BRET 
partners with untagged α1A-adrenergic receptor 
(α1AAR), a receptor that showed no detectable β-
arrestin binding (22). Stimulation with the selective 
α1AAR agonist A61603 induced β-arrestin2 binding 
to AT1R with comparable kinetics and extent as 
PMA (Figure 1d). Similar results were obtained 
with M3 muscarinic acetylcholine receptor 
(M3AChR) (Figure 1e), suggesting that this 
mechanism is not specific for α1AAR. Furthermore, 
since receptor tyrosine kinases also activate PKC, 
we co-expressed epidermal growth factor receptor 
(EGFR) with AT1R. As expected, EGF stimulation 
promoted β-arrestin2 binding to AT1R (Figure 1f). 
To prove the pivotal role of PKC in 
heterologous β-arrestin2 recruitment, we pretreated 
HEK 293T cells with a set of protein kinase 
inhibitors. Both the specific PKC inhibitor 
GF109203X and the broad-spectrum serine-
threonine kinase inhibitor staurosporine (used at a 
concentration that does not inhibit GRKs 
considerably (23)) prevented the PMA- or the 
α1AAR stimulation induced β-arrestin2 recruitment 
(Figure 2a). Similarly, the β-arrestin2 binding to 
AT1R promoted by M3AChR or EGFR activation 
was also sensitive to PKC inhibition (Figure S1a-
b). Although the C-tail of AT1R contains three 
known PKC phosphorylation sites, PKC may also 
act indirectly through activation of other kinases. It 
was reported that PKC can enhance the activity of 
GRK2 (24, 25), but inhibits GRK5 (26). Therefore, 
we tested whether PKC induces the AT1R-β-
arrestin2 binding via GRK2. Pretreatment with the 
GRK2/3 inhibitor compound 101 (Cmpd101) did 
not alter the PMA-triggered AT1R-β-arrestin2 
interaction, and it had only a slight effect in the case 
of α1AAR stimulation (Figure 2b). Furthermore, 
inhibition of several other potential downstream 
protein kinases did not prevent the heterologous β-
arrestin binding either. These results support the 
idea that the PKC effects are mainly direct. In 
addition, the MEK1/2 inhibitor PD98059 did not 
have any effect on heterologous recruitment either 
(Figure S1c and d), demonstrating that ERK 
cascade activation is not involved in the process, in 
contrast to the heterologous regulation of CXCR4 
receptor (27). Interestingly, the inhibition by 
Cmpd101 on the AngII-induced binding was only 
mild, but was significantly potentiated by 
staurosporine (Figure 2b), which is in good 
agreement with former observations that GRK and 
PKC phosphorylation sites overlap in AT1R. 
To test whether the PKC-induced β-
arrestin2 binding is dependent on constitutive 
receptor activity, we incubated cells with AT1R 
inverse agonist candesartan prior to PMA 
administration (Figure 2a). Candesartan 
pretreatment completely inhibited the AngII-
induced β-arrestin2 binding to AT1R, but did not 
prevent its heterologous stimulation, demonstrating 
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that this process is independent of the activation 
state of the receptor.  
Next, we examined whether stimulation of 
endogenous Gq/11 protein-coupled receptors could 
induce the observed phenomenon. Since we found 
instable and low calcium signaling of endogenous 
GPCRs upon lysophosphatidic acid, histamine, 
bradykinin, carbachol, or ATP stimulation in our 
HEK cells (data not shown), we tested the effects of 
purinergic receptor activation in COS-7 cells. We 
found a small, but significant elevation of the 
BRET signal between AT1R-Venus and Rluc8-β-
arrestin2 upon ATP stimulus (Figure 2c). The lower 
and earlier maximum of the signal was expected, 
since β-arrestin2 overexpression desensitizes the 
endogenous purinergic receptors, as shown by 
calcium measurements using a BRET-based Ca2+ 
biosensor (Figure 2d). 
 
Formation of the stability lock is required for β-
arrestin binding to inactive AT1R 
To investigate the stability of the 
interaction, i.e. whether it is class A- or class B-
type, we co-expressed Cerulean-tagged AT1R with 
β-arrestin2-Venus. Both AngII and PMA promoted 
translocation of β-arrestin2-Venus from diffuse 
cytoplasmic localization to the plasma membrane 
and then co-internalization to intracellular vesicles 
with AT1R (Figure 3a, left panel). Similarly, 
α1AAR-mRFP stimulation resulted in intracellular 
co-localization of AT1R and β-arrestin2 (Figure 
S2a). In contrast, the α1AAR-induced β-arrestin2 
redistribution was missing in absence of AT1R-
Cerulean co-expression. Since PKC activity 
induced a Class B-type interaction, we speculated 
that the residues, which are responsible for the 
stable receptor-β-arrestin interaction, play the 
decisive role in PKC-promoted β-arrestin2 binding. 
Previous studies showed that the stable β-
arrestin-AT1R interaction is dependent on a serine-
threonine cluster in the AT1R C-terminus (residues 
T332, S335, T336 and S338 (TSTS) (12, 28, 29)) 
and on two lysines (K11 and K12) in the β-strand I 
of the N-domain of β-arrestin2 (30), which are 
conserved phosphate-binding residues in all 
arrestins (31–35). Thus, we set out to test whether 
the same receptor and arrestin elements are 
involved in the PMA-induced β-arrestin2 binding. 
To this end, we replaced the amino acids of interest 
with alanines (AT1R-TSTS/A and K2A-β-arrestin2, 
respectively), and expressed either AT1R-TSTS/A 
with wild type β-arrestin2 or wild type AT1R with 
K2A mutant β-arrestin2, respectively. In both 
cases, receptor activation by AngII promoted only 
transient β-arrestin2 binding, as reflected by the 
absence of β-arrestin2 in intracellular vesicles 
(Figure 3a, middle and right panel). Moreover, 
BRET measurements showed that both mutations 
decreased the interaction to a similar extent (Figure 
3b). When the two mutants were co-expressed, no 
further decrease of the signal was observed, 
suggesting a direct interaction between the two 
regions. Furthermore, no detectable β-arrestin2 
binding could be observed upon PMA treatment in 
cells expressing AT1R-TSTS/A and/or K2A-β-
arrestin2 (Figure 3a and b). Conceivably, the same 
phosphorylation sites (TSTS) and phosphate-
binding arrestin residues (K11, K12) are engaged 
during the PKC-induced β-arrestin2 translocation 
and in the canonical agonist-induced β-arrestin2 
activation.  
To examine whether the affinity between 
receptor and β-arrestin2 was affected by these 
mutations, and the observed phenomena are not due 
to altered internalization, we investigated the 
stability of this interaction under internalization-
inhibited conditions using dominant-negative 
dynamin (36, 37). We induced β-arrestin2 binding 
by application of the AT1R agonist AngII, then 
added competitive antagonist candesartan to 
inactivate the receptors, and followed the rate of β-
arrestin dissociation using BRET. Both K2A- and 
TSTS/A mutations accelerated the detachment of β-
arrestin2 (Figure 3c), proving that these mutations 
weakened the interaction. This effect was even 
more pronounced when we used the low-affinity 
agonist angiotensin IV (AngIV) (38) (Figure S2b), 
which is displaced faster than AngII.  
The role of K11,12 in AT1 receptor binding 
was in contrast with the results obtained with other 
GPCRs, like β2-adrenergic, D1 dopamine and D2 
dopamine receptors (32). We speculated that this 
distinction may explain the different β-arrestin 
binding phenotypes of these receptors, i.e. AT1R is 
a prototypic class B receptor, whereas the other 
three subtypes belong to the class A. These results 
suggested that K11,12 in β-arrestin2 and distinct 
serine-threonine clusters of receptor C-termini form 
a stability lock, which is responsible for the stable 
binding between GPCRs and β-arrestins. In 
accordance with that, the K2A mutation in β-
arrestin2 prevented its intracellular appearance 
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after stimulation of V2R (Figure 4a), another 
prototypical class B GPCR. The phosphorylation-
deficient V2R-AAA (S362A, S363A, S364A) 
mutant showed similar Class A interaction with β-
arrestin2, as earlier described (13). Both V2R and β-
arrestin2 mutations decreased the binding, but their 
co-expression resulted in only a slight additional 
decline (Figure 4b, left panel). We observed no 
heterologous β-arrestin2 binding to V2R, probably 
because this receptor lacks target motifs for PKA or 
PKC (data not shown). 
We tested whether the β-arrestin2 
interaction with the class A β2-adrenergic receptor 
(β2AR) can be made K11,12-dependent. We used a 
mutant β2AR with engineered additional 
phosphorylation sites (β2AR-SSS; G361S, E362S, 
Q363S), which shows class B-type binding (39). 
The interaction phenotype of the mutant receptor 
was reversed to class A by K2A-β-arrestin2 (Figure 
4c). In agreement with these results, BRET signal 
between the mutant receptor and wild type β-
arrestin2 was elevated, but the increase was 
prevented by K2A mutation (Figure 4b, right 
panel). These results indicate that the formation of 
the stability lock between K11,12 in β-arrestin2 and 
phosphorylated S-T motifs in receptor C-termini, 
serves as a general mechanism for class B 
interaction. 
 
Conformation of active β-arrestin2 is interaction-
specific 
Next, we investigated whether the β-
arrestin2 conformation depends on the mode of 
receptor engagement. To follow the structural 
rearrangements of β-arrestin2, we generated a panel 
of intramolecular fluorescein arsenical hairpin 
binder (FlAsH)-BRET reporters. In these 
constructs, BRET signal is measured between two 
parts of the same protein, so that changes in the 
signal indicate conformational rearrangements 
within the molecule. The sensors have been 
designed in a way that the positions of the FlAsH 
binding cysteines match the previously published 
β-arrestin2 BRET and FRET sensors (40, 41) 
(Figure 5a). CCPGCC binding motifs for the FlAsH 
were incorporated after residues 139, 154, 225, 263 
or 410 (F139, F154, F225, F263 and F410 sensors, 
respectively). F139 and F154 are located within the 
N-domain of β-arrestin2, F225 and F263 are in the 
C-domain, whereas F410 is on the C-terminus. The 
donor molecule was fused to the N-terminus of β-
arrestin2, but in contrast to the previous publication 
(40), we used a brighter version of Renilla 
luciferase, Rluc8. Rluc8 has been shown to be 
advantageous for BRET measurements, since it is 6 
times brighter than conventional Renilla luciferase 
(42). This technical improvement prolonged the 
effective detection time, allowing us to detect the 
dynamics of BRET signal changes for at least 20 
minutes. To verify the binding of the sensors to AT1 
receptor, we co-expressed these chimeric proteins 
with AT1R-Venus in HEK 293T cells, and 
stimulated the receptors with AngII. In this setup, 
intermolecular BRET between the Rluc8-tag of β-
arrestin2-FlAsH sensor and the Venus-tag of AT1R 
is measured. As shown in Figure S3a, all sensors 
bind AT1R-Venus similarly, with the same kinetics 
as the control unmodified Rluc8-β-arrestin2 (Figure 
5b). Thus, the ability of β-arrestin to interact with 
AT1R was not affected by the insertion of CCPGCC 
motifs in the selected positions. Next, we 
investigated the conformational changes within the 
β-arrestin2 sensors during their activation. In these 
experiments, we co-expressed untagged AT1R with 
different FlAsH sensors and followed the 
intramolecular BRET between Rluc8 and FlAsH 
label. Upon stimulation with AngII, we detected 
BRET signal increase with F154, F410, and 
decrease with F139, F225, F263 (Figure S3a). The 
direction of F139, F225, F263 and F410 signal 
changes were identical to those previously 
described using the similar FlAsH sensors with 
AT1R (40).  
To facilitate the kinetic comparison of 
inter- and intramolecular BRET, we presented the 
signal changes as the percentage of the peak signals 
(Figure 5b), independently of the direction of 
BRET change. The kinetics of F139, F154 and 
F410 intramolecular BRET signals were similar to 
that of the receptor-β-arrestin2 intermolecular 
BRET, suggesting that the sensor-detected 
conformational changes occurred parallel with the 
interaction between the two proteins. However, in 
the case of the C-domain sensors (F225 and F263), 
the signals reached their maximum after a few 
minutes and then slowly decreased, in contrast to 
the AT1R-β-arrestin2 binding kinetics, which 
achieved a plateau and remained stable. These data 
suggest that the conformational rearrangements 
within the C-domain of β-arrestin2 do not end with 
receptor binding, but this part of the protein remains 
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dynamic and constantly changes at least for the 20 
minutes after stimulation.  
To test which conformational changes are 
promoted by the PKC-induced interaction, we 
measured the conformational rearrangements in β-
arrestin2 after PMA stimulation. As shown in 
Figure 6a and b, F139 and F154 BRET changes, 
when normalized to magnitude of β-arrestin2 
coupling (i.e. to intermolecular BRET), were 
similar to those after AngII stimulation, and their 
kinetics followed the β-arrestin2 binding to the 
receptor (Figure 5c). In contrast, F410 signal was 
reversed and lower, and the C-domain sensors 
(F225, F263) showed no changes compared to the 
unstimulated cells (Figure 6b). Thus, the 
conformation of the PMA-activated β-arrestin2 
bound to AT1R is static and significantly different 
from that induced by AngII. 
To explore the role of the stability lock in 
the conformational changes induced by the 
homologous activation, we used the AT1R and β-
arrestin2 mutants. First, AT1R-TSTS/A was co-
expressed with the intramolecular sensors. In this 
setup, F154 and F225 signals were abolished, 
whereas F263 and F410 signals were reversed upon 
AngII treatment (Figure 6c). Signal changes of 
F225 and F410 are in good agreement with the 
previous observation, that activation of these 
constructs correlates with the stability of the 
receptor-β-arrestin2 complex (40). Next, we 
constructed β-arrestin2-FlAsH sensors with K11A 
and K12A mutations (F139-K2A, F154-K2A, 
F225-K2A, F263-K2A and F410-K2A). Basal 
BRET ratios with F410-K2A were elevated 
compared to the wild type β-arrestin2 (Figure S3c). 
The altered basal conformation of K2A-β-arrestin2 
was expected, since it has been shown previously 
that K2 region binds the C-terminal part of arrestins 
to the N-domain in the inactive state (33, 43). 
Activation of β-arrestin2 results in the release of the 
C-terminus (44, 45), which might be reflected by 
BRET ratio change with F410 (Figure 6a), and also 
by altered basal BRET ratio with F410-K2A 
(Figure S3c). Strikingly, when we stimulated the 
AT1R co-expressing cells with AngII, a similar 
pattern of structural rearrangements was observed 
to that of AT1R-TSTS/A and wild type β-arrestin2: 
F154 and F225 signals were missing, F410 was 
reversed and F263 signal was abolished (Figure 
6d). Since changes in the structure of K2A-β-
arrestin2 are comparable to that of wild type β-
arrestin2 when AT1R-TSTS/A is expressed, these 
data indicate that TSTS region in AT1R directly 
interacts with K11 and K12 in β-arrestin2.  
As shown in the radial diagram of Figure 
6e, at least 3 active β-arrestin2 conformations can 
be clearly distinguished. The fully engaged 
conformation is different from the conformations 
induced by PKC or in the absence of the stability 
lock formation. These results also reveal the 
decisive role of the stability lock in structural 
rearrangements within β-arrestin2. Active stability 
lock is sufficient for promoting conformational 
changes and it has a prominent part in governing the 
full panel of structural realignments.  
 
PKC-activated β-arrestin2 dictates distinct fate of 
internalized receptor 
 The confocal images showed that PMA 
treatment promoted the endocytosis of AT1R. 
Internalized receptors either recycle after 
dephosphorylation, or are degraded in lysosomes 
(46). It has been shown previously that receptor-β-
arrestin interaction may regulate the receptor’s 
intracellular processing (47), so we hypothesized 
that PKC-induced β-arrestin drives intracellular 
receptor trafficking differently compared to the 
fully engaged form. To test this idea we used 
bystander BRET measurements between AT1R-
Rluc8 and one of the intracellular vesicle markers, 
Venus-Rab4, Venus-Rab5, Venus-Rab7 or Venus-
Rab11, as described previously (48, 49). Rab5 is 
located in the early endosomes, Rab4 and Rab11 in 
the fast and slow recycling vesicles, respectively, 
whereas Rab7 is found in late endosomes, which 
fuse with lysosomes (46). Increased BRET signals 
between AT1R-Rluc8 and all four Rab constructs 
were detected after both AngII and PMA treatment 
(Figure 7a-d), as well as after α1AR stimulation 
(Figure S4a-d), demonstrating the redistribution of 
AT1R from the cell membrane to intracellular 
vesicles. To better visualize the intracellular 
trafficking pattern, we presented the BRET ratio 
changes after 60-minute stimulation in a radial 
diagram (Figure 7e and Figure S4e). It shows that 
PKC-activated β-arrestin2 drives recycling with 
similar efficiency, but the degradation pathway is 
impaired compared to that of AngII. These data 
suggest that the PKC-induced β-arrestin2 activation 
promotes a distinct internalization pattern of AT1R, 
therefore receptor fate depends on the mode of β-
arrestin2 engagement. 
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Inactive receptor-bound β-arrestins recruit 
MAPKs 
Following the binding to certain GPCRs, β-
arrestin2 can recruit the members of the MAP 
kinase cascade (8). We investigated whether β-
arrestins bound to an inactive receptor retain this 
ability. To test this, we designed a BRET assay in 
which energy transfer was detected between AT1R-
Rluc8 and either ERK2-Venus or Venus-MEK1 
(Figure 8a). We measured increase in the BRET 
ratios between AT1R-Rluc8 and ERK2-Venus or 
Venus-MEK1 upon stimulation with AngII. 
Strikingly, when β-arrestin2 was co-expressed with 
the BRET pairs, AngII induced much more 
pronounced BRET signal elevation (Figure 8b), 
suggesting that proper stoichiometry of receptor, 
ERK, MEK and β-arrestin2 is required for the 
correct assembly of the signaling complex. This is 
in agreement with previous observation where 
JNK3 translocation to AT1R was detected (50). 
Interestingly, the kinetics of MEK1 and ERK2 
recruitment were similar to the dynamics of 
receptor-β-arrestin2 interaction (Figure 8c), and did 
not follow that of F263 (Figure 5b), which was 
suggested previously to correlate with ERK1/2 
activation (40). Strikingly, PMA stimulation led to 
a significant increase in the signal, although the 
amplitude was lower than that observed with AngII 
(Figure 8b) and was proportional to the magnitude 
of β-arrestin2 recruitment (Figure 8c). Similar 
effect was observed upon α1AAR activation (Figure 
8d). These data show that not only active receptors 
can participate in signal transduction, but inactive 
receptors can also serve as scaffold proteins for 
signaling complexes, representing a novel 
mechanism of receptor cross-talk. 
 
Discussion 
 GPCRs contact β-arrestins via two non-
exclusive interactions. One is the binding to the 
activated receptor’s helix bundle, whereas the other 
is mediated by the receptor-attached phosphates. 
Active conformation of the receptor and subsequent 
GRK-mediated phosphorylation are generally 
thought to be prerequisite for β-arrestin binding 
(16), suggesting that the two main interactions 
occur simultaneously. Recent studies have shown 
that the phosphate and the core interactions can be 
separated in vitro or by using receptor chimeras and 
mutants (51–53). However, the question remained 
whether the distinct interactions could be 
independent in physiologically relevant situations. 
Here we show that activation of PKC by 
PMA, stimulation of Gq/11-coupled GPCRs or 
EGFR initiates β-arrestin2 recruitment to AT1R. 
Upon receptor overexpression or direct PKC 
stimulation with PMA, the PKC activity may be 
well over the levels that are physiologically 
observed, and may lead to phosphorylation of 
proteins which are normally not targets of this 
kinase. Therefore, we also provide evidence that 
endogenous purinergic receptors can exert the same 
effect, proving that the interaction can be triggered 
at physiological levels of PKC activation. Since 
there are three consensus PKC phosphorylation 
sites in the C-tail of AT1R (S331, S338, and S348; 
S338 is part of the TSTS motif) (20, 28), and 
inhibitors of other protein kinases did not prevent 
the heterologous AT1R-β-arrestin2 interaction, we 
assume that PKC acts mainly via direct AT1R 
phosphorylation. However, we cannot rule out that 
other, PKC-activated kinases may also participate 
in this process.  
Although the homologous and 
heterologous mechanisms of β-arrestin recruitment 
to AT1R show common features, such as the 
dependence on the same phosphorylated residues in 
the receptor C-terminus, there are important 
differences: in addition to the different participating 
kinases, the heterologous mechanism does not 
demand the active state of the receptor. This was 
surprising, since receptor binding of β-arrestins, in 
contrast to visual arrestin (54), was assumed to 
require receptor activity (16). These results 
demonstrate that β-arrestins can bind either to the 
phosphorylated receptor C-terminus or to both 
sites.  
We found that the interaction only with the 
C-terminal phosphates on the receptor, a hallmark 
of class B receptors (15), was dependent on the 
stability lock. The stability lock is formed between 
phosphorylated C-terminal serine-threonine 
clusters in the receptor and two conserved lysines 
in β-arrestin2 N-domain. In the inactive state of β-
arrestins these lysines are shielded by the β-arrestin 
C-terminus. Receptor docking of arrestin induces 
the disruption of the “polar core” and displaces the 
β-arrestin C-terminus (44, 45). Thereafter, K11 and 
K12 can interact with phosphorylated residues of 
the receptor C-tail, thereby completing and 
maintaining the C-terminal swap, or rebind the 
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negatively charged β-arrestin C-terminus. This 
competition dictates the receptor-β-arrestin 
interaction stability: the presence of phosphorylated 
serine-threonine cluster favors the receptor binding, 
and the formed bonds stabilize the interaction. This 
model is supported by the previous observation that 
C-terminal truncation of β-arrestin1 enhances the 
binding to weakly interacting receptors (14). A 
former study showed that arginine replacement of 
K11 and K12 transforms the interaction phenotype 
with AT1R to class A but does not alter it in the case 
of V2R (30). This discrepancy may be explained by 
that the highly charged arginines bind the β-arrestin 
C-terminus with higher affinity and therefore do not 
allow the stable C-terminal swap in the case of 
AT1R. However, these lysines are not essential for 
the C-terminal swap, as there are receptors where 
β-arrestin binding is enhanced by phosphorylation, 
but K2A mutation does not significantly alter their 
interaction (32). Our data do not suggest that other 
basic residues of β-arrestin may not participate in 
formation of stabile interaction, but our results 
clearly demonstrate that the formation of K11,12-
dependent stability lock is necessary and sufficient 
to promote class B-type binding.  
Moreover, we found that the engagement 
of K11,12 not only stabilizes the interaction with 
the receptor C-tail, but also dictates the 
conformation of β-arrestin. PKC-phosphorylation 
was sufficient to induce conformational changes in 
β-arrestin2 N-domain. This role of K11,12 is in 
good agreement with the results of a previous study, 
where phosphopeptide-induced β-arrestin1 
conformational shifts were investigated (55). 
Interestingly, the C-domain sensors (F225, F263) in 
arrestin did not respond to the recruitment upon 
PKC-phosphorylation of the receptor or in the 
absence of stability lock, indicating that both 
stability lock and receptor activity are required for 
the full set of structural rearrangements in the C-
domain. The conformational change of the C-
domain seems to be a dynamically regulated 
process. We could not correlate the kinetic pattern 
of C-domain activation and MEK1/ERK2 
recruitment, however it does not rule out the 
intriguing possibility that dynamical 
conformational changes may play a role in the 
temporal regulation of β-arrestin interactions with 
effectors. It is tempting to speculate that the kinetics 
of conformational rearrangement of C-domain may 
reflect the dynamical change of posttranslational 
modifications, i.e. phosphorylation or 
ubiquitination (3) of β-arrestin2, but this idea needs 
to be experimentally tested. Our results also suggest 
that, besides C-terminal phosphorylation pattern, 
the conformational state of the helix bundle has also 
prominent role in governing the structural 
rearrangements in β-arrestins, thereby representing 
an important part of the receptor barcode. 
These data directly demonstrate the 
existence of multiple active β-arrestin 
conformations as proposed earlier (56). To the best 
of our knowledge, this is the first example, where 
two mechanisms, i.e. the canonical homologous 
and the novel heterologous activation, induce β-
arrestin binding to the same receptor in different 
conformations in a physiologically relevant setting. 
Previous studies suggested that the multiple active 
conformations of β-arrestins have different 
functions (55, 57, 58). This may explain our finding 
that the PKC-induced β-arrestin2 recruitment 
directed the receptor to Rab7-enriched late 
endosomes to a lesser extent than AngII. 
Interestingly, the heterologous β-arrestin2 
recruitment to α1B-adrenergic receptor was shown 
to promote late endosomal trafficking, indicating 
that this type of regulation exhibits receptor 
specificity (59). Additionally, in a previous study 
we showed that the intracellular fate of AT1R is 
ligand-specific (48). These observations support 
the idea that different β-arrestin conformations 
could be biased towards particular effectors. 
However, we cannot rule out that the observed 
difference may arise from the decreased receptor-β-
arrestin2 binding. Nonetheless, heterologous 
activated β-arrestin2 was also functionally active, 
capable to induce receptor internalization.     
Accumulating data have emphasized the 
pivotal role of β-arrestin2 in mediating the MAPK 
signaling of AT1R(21, 60, 61). In this function, β-
arrestin plays a role as a scaffold for the members 
of the signaling cascade. In contrast to JNK3, direct 
interaction between receptor and β-arrestin is 
required for the activation of ERK (62, 63). Recent 
data has shown that fully engaged β-arrestin 
binding to the GPCR is not required for this 
function, and at least core interaction is dispensable 
(52). In our experiments, although fully engaged 
form of β-arrestin2 was most efficient in binding 
MAPK cascade members, the PKC-activated form 
also resulted in the recruitment of MEK1 and ERK2 
to the receptor, expanding this observation, and 
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suggesting that the binding of β-arrestin to the 
receptor per se is critical for MEK/ERK 
recruitment. We also detected AT1R-β-arrestin2-
MAPK complex formation upon α1AAR 
stimulation. The assembly of the AT1R-β-arrestin2-
MEK-ERK complex induced by another receptor 
offers an intriguing mechanism by which a GPCR 
serves as a scaffolding protein rather than a signal 
initiator. The complex may serve as activator of 
ERK signaling or may simply change the 
localization of the cascade members. This 
mechanism, through AT1R or other GPCRs, may 
resolve the apparent discrepancy in previous studies 
showing that α1AAR does not interact with β-
arrestin2, but activates ERK β-arrestin2-
dependently (64). The data also show how the 
expression of one GPCR (e.g., α1AAR) with another 
(e.g., AT1R) can expand its signaling repertoire 
without the formation of receptor heteromers. 
Although observing the phenomena 
described in this paper between endogenously 
expressed proteins would strengthen our claims, 
detection of the AT1R-β-arrestin interaction in cell 
lines expressing AT1R endogenously is currently 
not possible. The only way of experimental 
detection would be co-immunoprecipitation, but to 
the best of our knowledge, no reliably working 
AT1R antibody is available to date. Nonetheless, 
effects of PKC activation on the function of 
endogenous AT1R have been previously observed 
in rat cardiac fibroblasts, cardiomyocytes and in a 
hepatic cell line (65–67). In these cells, activation 
of PKC by stimulation of vasopressin or 
lysophosphatidic receptors, or directly by PMA 
leads to the desensitization of AT1R through 
receptor phosphorylation. However, β-arrestin has 
never been demonstrated previously to bind to 
AT1R during heterologous desensitization. 
 In conclusion, we have shown that β-
arrestin2 can bind to the same GPCR in distinct 
active conformations in physiologically relevant 
circumstances. The results improve our 
understanding of the mechanics of β-arrestin 
activation. 
 
Experimental procedures 
Materials 
Molecular biology reagents and High Capacity 
NeutrAvidin Agarose Resin were from Thermo 
Scientific (Waltham, MA). Cell culture reagents 
were from Invitrogen (Carlsbad, CA). 
Coelenterazine h was obtained from Regis 
Technologies (Morton Grove, IL). Fluorescein 
arsenical hairpin binder-ethanedithiol (FlAsH-
EDT2) was from Santa Cruz Biotechnology (Dallas, 
TX). Biotin was from SERVA Electrophoresis 
GmbH (Heidelberg, Germany). Candesartan and 
compound 101 were from Tocris (Bristol, United 
Kingdom). Antibodies were from Cell Signaling 
Technologies (Danvers, MA). Protease inhibitor 
cocktail (cOmplete) was from Roche (Basel, 
Switzerland). Immobilon Western 
Chemiluminescent HRP Substrate was purchased 
from Millipore (Billerica, MA). Unless otherwise 
stated, all other chemicals and reagents were 
purchased from Sigma (St. Louis, MO). 
 
Plasmid DNA constructs 
The Renilla luciferase variant Rluc8 was a kind gift 
of Dr. Sanjiv Gambhir (68). To generate pRluc8-C1 
and pRluc8-N1 plasmids, the coding sequence of 
Rluc8 was PCR amplified and EYFP was replaced 
with Rluc8 in Clontech pEYFP-C1 and pEYFP-N1 
vectors using AgeI/BglII and AgeI/NotI restriction 
enzymes, respectively. β-arrestin2-GFP, β-
arrestin2 in pCMV5 vector, and dominant-negative 
(K44A-mutant) dynamin2A were kind gifts of Dr. 
Marc G. Caron, Dr. Stephen S. Ferguson, and Dr. 
Kazuhisa Nakayama, respectively. β-arrestin2-
Venus, β-arrestin2-Cerulean, Venus-Rab5, Super 
Renilla luciferase-tagged β2AR (β2AR-Sluc), 
EGFR, Cameleon D3 Ca2+ BRET biosensor, β2AR-
Cerulean, V2R-Sluc, M3AChR and α1AAR 
constructs were described previously (69–74). 
NES-BirA was produced by cloning the biotin 
ligase BirA from pcDNA3.1 MCS-BirA(R118G)-
HA (obtained from Abcam (Cambridge, UK)) with 
a nuclear export signal (PubMed PMID: 20972448, 
QVQAGELQGQLVDVH) attached to its N-
terminus and was placed in pEYFP-N1 vector 
between AgeI and NotI restriction sites. 
Subsequently, 118G was mutated back to R with 
precise gene fusion PCR.  
AT1R-Cerulean, AT1R-Rluc8, AT1R-TSTS/A-Rluc 
and AT1R-TSTS/A-Cerulean were created by 
exchanging Rluc to Cerulean or Rluc8 in AT1R-
Rluc and AT1R-TSTS/A-Rluc constructs (75), 
respectively. To generate AT1R-YFP-BAP, we 
amplified the coding sequence of YFP in frame 
fused with biotin acceptor peptide (BAP: 
MSGLNDIFEAQKIEWHE) with PCR, then Rluc 
was replaced with YFP-BAP in AT1R-Rluc. 
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Untagged AT1R in pEYFP-C1 vector was 
constructed by replacing EYFP with the coding 
sequence of rat AT1A receptor without the 
untranslated regions. The cloning strategy was the 
same for untagged AT1R-TSTS/A, carrying the 
T332A, S335A, T336A, S338A mutations. α1AAR-
mRFP was constructed by subcloning the open 
reading frame of α1AAR with GGGDPPVAT linker 
sequence into pmRFP-N1 backbone between KpnI 
and BamHI restriction sites. Precise gene fusion 
PCR was used to introduce S362,363,364A 
mutations into V2R-Sluc (V2R-AAA-Sluc) and 
G361S, E362S, Q363S mutations into β2AR-Sluc 
(β2AR-SSS-Sluc). Cerulean-tagged versions of 
these mutants and wild type V2R were generated by 
replacing Sluc to Cerulean using AgeI/NotI 
restriction enzymes. 
Venus-Rab4, Venus-Rab7 and Venus-Rab11 were 
created by replacing EYFP to monomeric Venus in 
YFP-Rab4, YFP-Rab7 and YFP-Rab11 constructs 
(48). To generate Rluc8-β-arrestin2, the coding 
sequence of rat β-arrestin2 was subcloned from 
YFP-β-arrestin2 (72) after Rluc8 with a short linker 
sequence (RSRAQACTR) into pRluc8-C1. Rluc8-
β-arrestin2-FlAsH sensors (F139, F154, F225, 
F263, F410) were constructed by inserting the 
CCPGCC amino acid motif after the 139th, 154th, 
225th, 263rd or 410th positions of β-arrestin2 using 
precise gene fusion PCR, the positions were 
selected based on earlier studies using similar 
sensors (40, 41). The K2A-β-arrestin2 mutants 
were made analogously to bovine K2A-β-arrestin2 
(32); K11A and K12A mutations were introduced 
to rat β-arrestin2 by precise gene fusion PCR to 
create K2A-β-arrestin2-Venus and Rluc8-K2A-β-
arrestin2. K2A mutation was inserted into F139, 
F154, F225, F263, F410 constructs by exchanging 
Rluc8 and the beginning of β-arrestin2 coding 
sequence using AgeI and PstI restriction enzymes 
with the identical sequence of Rluc8-K2A-β-
arrestin2. ERK2-Venus and Venus-MEK1 
constructs were kind gifts of Dr. Attila Reményi. 
 
Cell culture and transfection 
HEK 293T and COS-7 cells were from American 
Type Culture Collection (ATCC CRL-3216 and 
CRL-1651, respectively). The cells were cultured in 
DMEM supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin. For co-
precipitation and BRET measurements, cells were 
transfected in suspension using Lipofectamine 
2000 according to manufacturer’s protocol and 
plated on 10 cm cell culture dishes or white 96-well 
plates, respectively. In the case of HEK 293T cells. 
poly-L-lysine coated plates were used. For 
immunoblotting and confocal microscopy, cells 
were plated the day before transfection, and the 
transfection was performed on adherent cells. Cells 
were not tested for mycoplasma contamination. 
 
Co-precipitation experiments 
HEK 293T cells were transfected in suspension 
with plasmids encoding NES-BirA (biotin ligase), 
β-arrestin2-Cerulean and/or AT1R-YFP-BAP. 24 
hours after transfection 150 µM biotin was added 
for 20-24 hours to allow substantial biotinylation of 
AT1R-YFP-BAP. Serum and the excess of biotin 
were removed by changing the media to DMEM 
supplemented with antibiotics and 1% bovine 
serum albumin. Cells were serum-starved for 2-4 
hours, then were stimulated for 20 minutes at 37°C. 
Reactions were stopped by placing the dishes to ice 
and washing with ice cold phosphate buffered 
saline (PBS) solution. Washing step was repeated 5 
times. Then the cells were lysed with RIPA buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton 
-100, 0.1% SDS, 0.25% sodium deoxycholate, 1 
mM EDTA,) supplemented with cOmplete 
Protease Inhibitor cocktail (Roche) and 
Phosphatase Inhibitor Cocktail 3 (Sigma). Lysates 
were collected, rotated for 15 minutes at low speed, 
then centrifuged at 20800 G for 10 minutes. 
Supernatants were incubated with 30 µl High 
Capacity NeutrAvidin Agarose Resin for 30 
minutes at 4 °C, then the beads were washed 3 times 
with ice-cold supplemented RIPA and once with 
PBS. The beads were resuspended in PBS. YFP and 
Cerulean fluorescence intensities were determined 
by exciting at 510 nm or 435 nm and measuring 
emission at 535 nm or 480 nm, respectively, using 
Thermo Scientific Varioskan Flash multimode 
plate reader. Fluorescent images from the 
NeutrAvidin beads were made with Zeiss LSM 710 
confocal laser-scanning microscope using a 20x 
objective. 
 
Bioluminescence resonance energy transfer 
measurements 
All the BRET measurements were performed on 
adherent cells, the measurements were made 24-28 
hours or 44-48 hours post-transfection in the case 
of HEK 293T or COS-7 cells, respectively. The 
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cells were washed, and the culture medium was 
changed to modified Kreb’s-Ringer medium (120 
mM NaCl, 10 mM glucose, 10 mM Na-HEPES, 4.7 
mM KCl, 1.2 mM CaCl2, 0.7 mM MgSO4, pH 7.4). 
Intermolecular BRET was detected between 
Renilla luciferase (Sluc or Rluc8)- and Venus-
tagged proteins. First, we measured Venus 
fluorescence intensity by exciting at 510 nm and 
measuring emission at 535 nm using Thermo 
Scientific Varioskan Flash multimode plate reader. 
Luminescence intensity was recorded after addition 
of Renilla luciferase substrate coelenterazine h (5 
µM) every 70 seconds for 24 minutes using 530 and 
480 nm filters at 37 °C. To calculate BRET ratio 
change, the vehicle-stimulated BRET ratio was 
subtracted from stimulus-induced BRET ratio. For 
quantification, we determined the average BRET 
ratio change in the first 24 minutes after 
stimulation. The total luminescence was 
determined without filter. BRET titration 
experiments and candesartan-induced β-arrestin2 
dissociation measurements were made in duplicate, 
all other BRET measurements were performed in 
triplicate. 
To detect conformational changes of Rluc8-β-
arrestin2-FlAsH sensors, the cells were washed 
three times with modified Kreb’s-Ringer medium. 
Thereafter, an earlier described labeling procedure 
(76) was adapted for 96-well plate measurements. 
Briefly, FlAsH-EDT2 was incubated with 
ethanedithiol (EDT) for 5 minutes at room 
temperature (1 mM and 12.5 mM diluted in DMSO, 
respectively), to assure that all FlAsH molecules are 
in FlAsH-EDT2 form. Then the cells were labeled 
with 500 nM FlAsH-EDT2 (together with 12.5 µM 
EDT and 0.1% (vol/vol) DMSO in modified 
Kreb’s-Ringer solution) for 1 hour at room 
temperature. After labeling, the excess and non-
specifically bound FlAsH dye was removed by 
changing the labeling medium to Kreb’s-Ringer 
solution containing 250 µM EDT for 10 minutes. 
Next, the cells were washed three times with 
Kreb’s-Ringer medium, and the same BRET 
measurement procedure was used as for the 
intermolecular BRET experiments. Intramolecular 
BRET was measured between Rluc8-tag and FlAsH 
label of the sensor. 
Since the amplitude of intramolecular BRET 
change is dependent on the number of the activated 
β-arrestins, we calculated relative FlAsH signals: 
the stimulus-induced intramolecular BRET change 
was normalized to the intermolecular BRET change 
(measured between Rluc8-tag of the sensor and 
Venus-tagged receptor in separate experiments), 
which is proportional to the quantity of activated 
molecules. 
 
Expression of the wild type and mutant BRET 
constructs  
The expression of the wild type and mutant donor 
or acceptor constructs was compared by the 
determination of the total luminescence or Venus 
fluorescence, respectively. The expression data are 
shown in Figure S5.  
 
Confocal laser-scanning microscopy 
To obtain confocal images from living cells, HEK 
293T cells were plated on poly-L-lysine coated 
glass coverslips. The next day the cells were 
transfected with plasmids encoding fluorescently 
labeled receptors and β-arrestin2. 24 hours after 
transfection, the medium was changed to modified 
Kreb’s-Ringer and the localization of the probes 
was examined in living cells at 37 °C with Zeiss 
LSM 710 confocal laser-scanning microscope 
using a 63x objective.  
 
Immunoblotting 
The reactions were stopped by placing the 6-well 
plates on ice and washing each well twice with ice-
cold PBS. Cells were scraped into SDS sample 
buffer, briefly sonicated, and heated for 15 minutes 
at 95°C. Proteins were separated by SDS 
polyacrylamide gel electrophoresis and were 
transferred to PVDF membranes. The membranes 
were blocked in 5% w/v fat-free milk powder in 
PBS with 0.05% v/v Tween 20 (PBST) for 1 hour 
at room temperature and incubated with primary 
antibody (diluted in PBST containing 5% fat-free 
milk powder) overnight at 4 °C. The membranes 
were washed 3 times with PBST for 10 minutes, 
then incubated with HRP-linked secondary 
antibody (goat anti-mouse or goat anti-rabbit, 
1:5000 diluted in PBST containing 5% fat-free milk 
powder) for 1 hour at room temperature and washed 
3 times. The antibodies were visualized using 
enhanced chemiluminescence. First the membranes 
were incubated with mouse anti-phospho-p44/42 
MAPK (T202, Y204) primary antibody (#9101, 
Cell Signaling) and developed, then the membranes 
were stripped using a guanidine hydrochloride-
based stripping solution (77). Thereafter total 
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ERK1/2 amount was determined using rabbit anti-
p44/42 MAPK (#9102, Cell Signaling) antibody.  
 
Statistical analysis 
No statistical methods were used to predetermine 
the sample size. The sample size (n) in figure 
legends refers to the number of independent 
experiments (biological replicates), all data points 
were included in the statistical analyses. The 
experiments were not randomized and the 
investigators were not blinded. GraphPad Prism 
software was used for graph construction, statistical 
analysis, and curve fitting. Unless otherwise stated, 
data are presented as mean+s.e.m. Paired two-
sample two-tailed Student’s t-tests or repeated 
measures One-Way ANOVA with Bonferroni post 
hoc-test were performed to compare the stimulus-
promoted signals with the vehicle-stimulated 
controls. The effects of inhibitors on stimulus-
induced signals were analyzed using Two-Way 
ANOVA with Bonferroni post hoc-test, significant 
inhibitory effect was concluded if the P value of 
interaction was less than 0.05. The binding ability 
of the wild type biosensors to AT1R was compared 
using One-Way ANOVA with Bonferroni post hoc-
test. The same statistical test was used to compare 
the expression of all biosensors. The expression of 
the wild type and mutant receptors were compared 
with two-sample two-tailed Student’s t-tests. The 
effect of K2A mutation on the basal intramolecular 
BRET ratio of the biosensors was analyzed with 
repeated measures One-Way ANOVA with 
Bonferroni post hoc-test. The relative, interaction-
normalized FlAsH signals were considered 
significant if the mean value was different from 0 
(P<0.05), analyzed with one-sample t-test, paired 
two-sample two-tailed t-tests were always 
performed simultaneously on the raw data. 
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Figure Legends 
 
Figure 1. β-arrestin2 binds to unliganded AT1R upon PKC activation 
a, PKC activation triggers β-arrestin2 binding to AT1R. HEK 293T cells were co-transfected with plasmids 
encoding NES-BirA (biotin ligase), β-arrestin2-Cerulean and/or AT1R-YFP-BAP, as indicated. After 20-
minute stimulation with 100 nM angiotensin II (AngII) or 100 nM phorbol myristate acetate (PMA), the 
cells were lysed and biotin-labeled AT1R was pulled down using NeutrAvidin beads. Left panel: YFP- and 
Cerulean fluorescence of the co-precipitated proteins. The values were normalized to the autofluorescence 
of the beads. n=3, *,P<0.05, analysed with One-Way-ANOVA (repeated measures, vs. control samples 
containing AT1R-YFP-BAP) with Bonferroni post hoc-test. Scatter dot plots with columns (mean+s.e.m.) 
are shown. Right panel: Representative images show the YFP (top) and Cerulean (bottom) fluorescence of 
the pulled-down proteins bound to the surface of the beads, recorded with confocal microscope. Scale bar 
represents 100 µm.  
b, Schematic representation of the used BRET set-ups with the applied stimuli. c-f, Kinetics of β-arrestin2 
binding to AT1R upon PKC activation.  Intermolecular BRET was measured between AT1R-Rluc8 and β-
arrestin2-Venus after AngII (c-f), PMA (c and d), or α1AAR agonist A61603 (1 µM, d), M3AChR agonist 
carbachol (10 µM, e), or EGF (100 ng/ml, f) treatments in every 70 seconds in cells co-expressing the 
indicated constructs. Stimulus-induced BRET ratio change was calculated by subtracting the corresponding 
vehicle-stimulated control. Kinetic curves are shown in c (n=6) and in d-f (n=3), data are mean+s.e.m. of 
independent biological replicates. 
 
Figure 2. The heterologous β-arrestin2 recruitment to AT1R is PKC phosphorylation-dependent, but 
does not require the active state of the receptor 
a-b, Heterologous β-arrestin2 binding to inactive AT1R is dependent on PKC activity. HEK 293T cells, co-
expressing AT1R-Rluc8, β-arrestin2-Venus and untagged α1AAR, were pretreated with the indicated 
inhibitors, and were stimulated with AngII, PMA or A61603. Scatter dot plots with columns (mean+s.e.m.) 
show the average BRET changes (area under curve) in the first 24 minutes after stimulation. In a, the cells 
were pretreated with PKC inhibitor GF109203X (2 µM), broad-spectrum kinase inhibitor staurosporine 
(500 nM), AT1R inverse agonist candesartan (10 µM), or vehicle (DMSO) for 30 minutes. The PMA or 
A61603 induced signals were hindered by PKC inhibition, but were not altered by the AT1R antagonist 
pretreatment. In b, the pretreatments were vehicle (DMSO), Src-kinase inhibitor PP1 (1 µM), 
Ca2+/calmodulin-dependent protein kinase II inhibitor CK-59 (20 µM); EGFR tyrosine kinase inhibitor AG-
1478 (10 µM), p38 MAPK inhibitor SB203580 (20 µM), 1 µM JAK Inhibitor I (inhibitor of JAK kinases), 
GRK2/3 inhibitor Compound 101 (Cmpd101, 30 µM), and co-pretreatment with Cmpd101 and 
staurosporine. The non-PKC inhibitors did not prevent the heterologous β-arrestin2 recruitment, suggesting 
that the PKC effects are mainly direct. The homologous binding was inhibited most efficiently by the co-
pretreatment with Cmpd101 and staurosporine, which is in good agreement with the previous observations 
that the GRK and PKC target sites overlap, and suggests that phosphorylation of AT1R by either kinase is 
sufficient for β-arrestin recruitment. *,P<0.05 means significant interaction between the effects of 
pretreatment and stimulation, #,P<0.05 means significant interaction between Cmpd101 and staurosporine 
treatments, analyzed with Two-Way ANOVA. Scatter dot plots with columns (mean+s.e.m.) are shown, 
n=3-4. 
c, Stimulation of endogenous Gq/11 protein-coupled receptors evoke β-arrestin2 binding to AT1R. COS-7 
cells were co-transfected with AT1R-Venus and Rluc8-β-arrestin2, and BRET was measured 48 hours after 
transfection. 50 µM ATP was used to stimulate the endogenous purinergic receptors. ATP induced 
significant increase of the BRET signal (average BRET ratio was compared to non-stimulated control using 
paired two-sample two-tailed t-test, P<0,05, n=3). d, Overexpression of β-arrestin2 desensitizes the 
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endogenous purinergic receptors in COS-7 cells. COS-7 cells were co-transfected with Cameleon D3 Ca2+ 
BRET biosensor and empty vector pcDNA3.1 or untagged β-arrestin2. The Ca2+ signal was lower and was 
terminated earlier in the case of β-arrestin2 co-expression.  Data are mean+s.e.m. 
 
Figure 3. PKC-triggered β-arrestin2 recruitment to AT1R requires stable binding to receptor C-
terminus  
a, The PMA-induced stable binding between AT1R and β-arrestin2 depends on the interaction stabilizing 
elements. Images were taken with confocal microscope from cells co-expressing wild type (WT) or 
phosphorylation-deficient (TSTS/A)-mutant AT1R-Cerulean and WT or phosphate binding-deficient 
(K2A)-mutant β-arrestin2-Venus, as indicated, before (control, top) and after 20-minute stimulation with 
PMA (bottom) or after 20-minute treatment with AngII (middle). Both PMA and AngII induced the co-
translocation of AT1R-WT-Cerulean and WT-β-arrestin2-Venus to endosomes. In contrast, both TSTS/A- 
and K2A-mutations evoked only plasmalemmal binding after AngII treatment, and prevented the PMA-
triggered interaction. Arrowheads mark β-arrestin2-enriched intracellular vesicles (class B-type binding), 
arrows point to plasma membrane-localized β-arrestin2 (class A interaction). Representative images are 
shown, n=3.  
b, Role of the stability lock in AT1R-β-arrestin2 binding. BRET titration experiments were performed. WT 
or TSTS/A-mutant AT1R-Rluc8 was co-transfected with increasing amounts of plasmid encoding WT- or 
K2A-β-arrestin2-Venus, as indicated. Stimulus (AngII, left panel or PMA, right panel)-evoked average 
BRET ratio changes (mean value of duplicate) are plotted as the function of fluorescence/luminescence 
ratio, n=3. One-site specific binding curves were fitted on the values. The AngII-triggered β-arrestin2 
recruitment was partially, and the PMA-induced recruitment was fully abolished by these mutations.  
c, Disruption of the stability lock decreases the stability of AT1R-β-arrestin2 interaction. BRET was 
measured between WT or TSTS/A-mutant AT1R-Rluc8 and WT- or K2A-β-arrestin2-Venus in cells co-
expressing dominant-negative dynamin, an internalization inhibitor. The interaction was induced by ~20-
minute treatment with 100 nM AngII, thereafter 10 µM competitive antagonist candesartan (Cand) was 
added to displace AngII. Both TSTS/A- and K2A-mutations accelerated the BRET ratio drop, indicating 
faster dissociation of β-arrestin2 from AT1R.  Values are presented as percentage of the peak AngII-induced 
signal in each experiment and each set-up as mean+s.e.m., n=3.  
 
 
Figure 4. Formation of the stability lock is necessary for the class B-type β-arrestin binding of GPCRs 
a, Stable binding between V2R and β-arrestin2 depends on K11,12 in β-arrestin2 and a receptor C-terminal 
serine-threonine cluster. Confocal images were taken from cells co-expressing Cerulean-tagged WT or 
phosphorylation-deficient AAA (S362,363,364A)-mutant V2R and WT- or K2A-β-arrestin2-Venus, as 
indicated, before and after 20-minute stimulation with 100 nM arginine-vasopressin (AVP). Both AAA and 
K2A-mutations changed the binding phenotype to class A.  
c, Class B-type interaction of phosphorylation-site engineered β2AR mutant is reversed to class A by K2A-
mutation in β-arrestin2. Cells were co-transfected with plasmids encoding WT (class A)- or SSS (G361S, 
E362S, Q363S)-mutant (class B) β2AR-Cerulean, WT- or K2A-β-arrestin2-Venus, and with untagged 
GRK2. Images were taken before and after 10 µM isoproterenol (ISO) stimulation for 20 minutes. K2A-
mutation prevented the appearance of β-arrestin2 in intracellular vesicles. Arrowheads mark β-arrestin2-
enriched endosomes, arrows point to β-arrestin2 translocated to the plasma membrane. Representative 
images of 3 independent experiments are shown. Scale bars represent 5 µm. 
b, K11,12 participates in the β-arrestin2 binding of class B GPCRs. BRET titration experiments were 
performed to elucidate the role of K11,12 of β-arrestin2 in the binding to the following Sluc-tagged 
receptors: WT (class B) or phosphorylation-deficient (AAA, class A) mutant V2R (left panel) and WT (class 
A) or phosphorylation-site engineered (SSS, class B) β2AR (right panel). BRET acceptors were WT- or 
K2A-β-arrestin2-Venus, as indicated. GRK2 was co-expressed in the case of β2AR experiments. 100 nM 
V2R agonist arginine-vasopressin and 10 µM β2AR agonist isoproterenol were used as stimuli, n=3. One-
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site specific binding curves were fitted on the data values. K2A-mutation decreased the binding of class B 
GPCRs substantially. 
 
Figure 5. Real time monitoring of recruitment and conformational changes of β-arrestin2  
a, Schematic representation of FlAsH-based β-arrestin2 BRET biosensors based on crystal structure of 
bovine β-arrestin2 (Protein Data Bank accession number: 3P2D (78)). Rluc8 was fused to the N-terminal 
end of β-arrestin2 and CCPGCC amino acid motifs for FlAsH-binding were inserted into rat β-arrestin2 
after the indicated amino acid positions (F139, F154, F225, F263 and F410, the corresponding residues of 
bovine β-arrestin2 are highlighted, 410 is marked after the last amino acid (393) of the solved structure).  
b and c, Dynamics of AT1R-β-arrestin2 interaction and β-arrestin2 conformational changes. Intermolecular 
BRET (interaction) was measured between AT1R-Venus and Rluc8-β-arrestin2 or FlAsH sensors, as 
indicated, upon AngII (b) or PMA (c) stimulation (F154, n=4; others, n=6). The intramolecular BRET 
(conformation) was followed in cells expressing untagged AT1R and β-arrestin2 biosensors labeled with 
FlAsH dye. (AngII: n=10, F139; n=7, F154; n=9, F225, F263, F410; PMA: n=8, F139, F225, F263, F410; 
n=6, F154). All experiments were performed in triplicate. BRET ratio changes are expressed as the 
percentage of the peak AngII-induced signal of each set-up. Values presented as mean+s.e.m. The kinetics 
of interaction and conformational changes upon AngII stimulation were similar in the case of N-domain 
(F139, F154) and C-terminal (F410) sensors. In contrast, the C-domain (F225, F263) sensors showed earlier 
peak in the conformational BRET change than in interaction, indicating that the conformational 
rearrangements in the C-domain are dynamic and constantly change. Upon PMA stimulation, N-domain, 
but not the C-domain sensors showed conformational changes, and their kinetics were similar to that of the 
binding. 
 
Figure 6. Structural rearrangements in β-arrestin2 are dependent on the mode of activation 
a-d, Patterns of conformational changes upon different modes of AT1R-β-arrestin2 binding. Since the 
number of interacting and activated β-arrestin molecules are different in case of the distinct activation 
modes, to facilitate the comparison, interaction-normalized relative FlAsH signals are shown (average 
conformational BRET ratio change divided by average interactional BRET change). The average inter- und 
intramolecular BRET ratio changes are presented in Figure S3.  
a and b, Conformational realignments in β-arrestin2 upon homologous and heterologous activation.  
Conformational BRET ratio changes were measured in cells expressing untagged wild type AT1R and wild 
type sensors labeled with FlAsH dye (AngII: n=10, F139; n=7, F154; n=9, F225, F263, F410; PMA: n=8, 
F139, F225, F263, F410; n=6, F154).  
c and d, Stability lock governs the conformational realignments in active receptor-bound β-arrestins. 
TSTS/A-mutation in AT1R (c) and K2A-mutation in β-arrestin2 (d) altered the FlAsH sensor activation 
profile upon AngII treatment similarly. Identical BRET set-ups were used as in panel a, with the indicated 
mutant constructs. n=5 and n=6 in the case of conformational BRET measurements with AT1R-TSTS/A 
and K2A-FlAsH biosensors, respectively, and interactional BRET was determined in 3 independent 
biological replicates. Scatter dot plots with columns (mean+s.e.m.) are shown, *,P<0.05, column means are 
significantly different from 0 value, analyzed with one-sample t-test.  
e, Web of β-arrestin2 conformational changes induced by fully engaged interaction (AngII), only C-
terminal interaction (PMA), or in absence of stability lock formation (AT1R-TSTS/A or K2A-β-arrestin2). 
The relative average FlAsH signals were normalized to the AngII-induced signals in the case of wild type 
AT1R and biosensors, then the values were cube root transformed and plotted in radial diagram, as 
indicated. Patterns of at least 3 active conformations can be distinguished. 
 
Figure 7. Homologous and heterologous β-arrestin recruitment to AT1R governs the intracellular 
receptor fate differently  
a-d, Appearance of AT1R in Rab-enriched compartments triggered by homologous or heterologous β-
arrestin2 activation. Cells were co-transfected with plasmids encoding wild type AT1R-Rluc8, Venus-Rab 
construct (Rab5 – early endosome marker (a), Rab4 – rapid recycling and early endosome marker (b), Rab7 
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– multi vesicular body/late endosome marker (c), Rab11 – late recycling route marker (d)) and untagged 
wild type β-arrestin2. AngII or PMA were used as stimuli. Both PMA and AngII induced the appearance 
of AT1R in all the tested Rab-enriched compartments. β-arrestin2 was co-transfected, since the relatively 
low level of endogenous β-arrestin2 limited the internalization of overexpressed AT1R-Rluc8.  Values are 
presented as mean+s.e.m, n=3.  
e, Patterns of intracellular AT1R redistribution after homologous and heterologous β-arrestin2 activation. 
BRET changes after 60±2 minute-stimulation were normalized to the AngII-induced values, and are 
presented in a radial diagram. PMA-induced less trafficking of AT1R to Rab7-enriched vesicles.  
 
Figure 8. β-arrestin2 bound to PKC-phosphorylated AT1R promotes the formation of AT1R-β-
arrestin2-MAPK complexes 
a, Schematic representation of the experimental set-up for detection of MAPK recruitment to AT1R. 
b, Intermolecular BRET was measured in cells co-expressing AT1R-Rluc8, Venus-tagged MAPK proteins 
(Venus-MEK1, left panel or ERK2-Venus, right panel) and empty vector pcDNA3.1 or β-arrestin2 after 
AngII or PMA treatment. Scatter dot plots with columns (mean+s.e.m.) of independent biological replicates 
(n=6, AngII; n=3, PMA) are shown, *,P<0.05, stimulus-induced BRET signal is significantly different from 
vehicle-stimulated control, analyzed with paired two-tailed two-sample t-test. c, Kinetics of MAPK 
recruitment to AT1R. Intermolecular BRET ratio changes upon AngII or PMA stimulation in the case of 
the different BRET setups are shown as percentage of the maximal AngII-induced signal averaged from 6 
experiments. The indicated BRET set-ups are AT1R-β-arrestin2 interaction (BRET between AT1R-Rluc8 
and β-arrestin2-Venus) and the recruitment of MAPK to AT1R (BRET signal in cells co-expressing AT1R-
Rluc8, untagged β-arrestin2 and Venus-MEK1 (left panel) or ERK2-Venus (right panel), as indicated, n=6). 
The kinetics of β-arrestin2-dependent MAPK recruitment to AT1R was similar and the magnitude was 
proportional to the receptor-arrestin interaction.  
d, Cells were co-transfected with plasmids encoding AT1R-Rluc8, α1AAR, Venus-MEK1 (left panel) or 
ERK2-Venus (right panel), and empty vector control (pcDNA3.1) or untagged β-arrestin2, as indicated. 
AngII and α1AAR agonist A61603 were used as stimuli. Average BRET ratio changes are presented in 
scatter dot plots with columns (mean+s.e.m., n=7). *,P<0.05 (vs. vehicle-stimulated control), analyzed with 
paired two-tailed two-sample t-test. 
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